[Congressional Bills 108th Congress]
[From the U.S. Government Publishing Office]
[H.R. 1956 Introduced in House (IH)]
108th CONGRESS
1st Session
H. R. 1956
To amend part B of title XVIII of the Social Security Act to provide
coverage of certain self-administered intramuscular and subcutaneous
drugs under the Medicare Program.
_______________________________________________________________________
IN THE HOUSE OF REPRESENTATIVES
May 6, 2003
Mr. Greenwood (for himself, Mr. Waxman, Mr. Van Hollen, Mr. Gutierrez,
Mr. Frank of Massachusetts, Mr. Holt, Mr. Frost, Mr. McNulty, Mr.
Doyle, Mr. Kildee, Mr. Kennedy of Rhode Island, Mr. Owens, Ms.
Schakowsky, Ms. Slaughter, Mr. Sanders, Mr. Pallone, Mr. Israel, Mr.
Collins, Mr. Ferguson, Mr. Rangel, Mr. Engel, Mr. Leach, Mr.
Nethercutt, Mr. Bishop of New York, and Mr. Moran of Virginia)
introduced the following bill; which was referred to the Committee on
Energy and Commerce, and in addition to the Committee on Ways and
Means, for a period to be subsequently determined by the Speaker, in
each case for consideration of such provisions as fall within the
jurisdiction of the committee concerned
_______________________________________________________________________
A BILL
To amend part B of title XVIII of the Social Security Act to provide
coverage of certain self-administered intramuscular and subcutaneous
drugs under the Medicare Program.
Be it enacted by the Senate and House of Representatives of the
United States of America in Congress assembled,
SECTION 1. COVERAGE OF CERTAIN SELF-ADMINISTERED INTRAMUSCULAR AND
SUBCUTANEOUS DRUGS UNDER THE MEDICARE PROGRAM.
(a) In General.--Section 1861(s)(2) of the Social Security Act (42
U.S.C. 1395x(s)(2)) is amended --
(1) by striking ``and'' at the end of subparagraph (U);
(2) by inserting ``and'' at the end of subparagraph (V);
and
(3) by adding at the end of the following new subparagraph:
``(W) in the case of a disease where an intramuscular
biological therapy has approval of the Federal Food and Drug
Administration for patient self-administration upon physician
determination of appropriateness and is covered under
subparagraph (A) or (B) of this paragraph, any intramuscular
and subcutaneous drug and biological with a similar approved
use by such Administration (including the same biological
delivered by intramuscular injection which is covered by either
such subparagraph) without regard to whether there is medical
or other supervision with respect to the administration of such
drug or biological;''.
(b) Effective Date.--The amendments made by subsection (a) shall
apply to drugs furnished on or after January 1, 2004.
<all>
Introduced in House
Introduced in House
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Referred to the Subcommittee on Health.
Referred to the Subcommittee on Health.
Llama 3.2 · runs locally in your browser
Ask anything about this bill. The AI reads the full text to answer.
Enter to send · Shift+Enter for new line